Patients' preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover study

Figures & data

Figure 1. Study design: A 12-week, randomized, crossover, multinational, open-label study.

Figure 2. Patient flow diagram.

Table I. Demographic characteristics of patients in primary and secondary analyses

	All patients	Started from ODT	Started from OCT
Total, N (%)	207 (100)	101 (100)	106 (100)
Sex, male, N (%)	131 (63.3)	61 (60.4)	70 (66.0)
Caucasian, N (%)	131 (63.3)	66 (65.3)	65 (61.3)
Hispanic, N (%)	54 (26.1)	24 (23.8)	30 (28.3)
Other, N (%)	22 (10.6)	11 (10.9)	11 (10.4)
Age, mean±SD	35.3±11.1	35.2±10.4	35.5±11.8
Weight, kg, mean±SD	75.0±14.9	73.2±14.3	76.8±15.3
BMI kg/m^2, mean±SD	26.9±5.0	26.5±5.0	27.3±4.9

Table II. Patient preference for olanzapine formulation by treatment sequence.

	All, N (%)	Started from ODT, N (%)	Started from OCT, N (%)
Total preference	175 (100)	85 (100)	90 (100)
Preference period II	55 (31.4)	40 (47.1)*	15 (16.7)*
Preference period III	99 (56.6)	33 (38.8)*	66 (73.3)*
No preference expressed	21 (12.0)	12 (14.1)	9 (10.0)

*P<0.001 from chi-square test for preference by treatment sequence association indicates difference in preference between formulations. Patients who expressed no preference were excluded from the test.

Table III. Number of patients with adverse events by treatment and study period (safety population).

	Started from ODT		Started from OCT		Pooled by treatment
AEs by MedDRA version 9.1	Period II (ODT)	Period III (OCT)	Period II (OCT)	Period III (ODT)	ODT	OCT
Total patients treated, N (%)	130 (100)	116 (100)	135 (100)	120 (100)	250 (100)	248 (100)
Total patients with at least one AEs, N (%)	27 (20.8)	7 (6.0)	24 (17.8)	15 (12.5)	42 (16.8)*	31 (12.5)*

*P=0.3.